Heterocyclic aspartyl protease inhibitors
Disclosed are compounds of the formula Ior a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein    Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic m1 agonist or m2 antagonist.
Schering Corporation Pharmacopeia Inc.
A C A C A C C C A A A C A C C A C A C A C A A A
A61P C07D A61P C07D A61P C07D C07D C07D A61P A61P A61P C07D A61P C07D C07D A61K C07D A61P C07D A61P C07D A61P A61K A61P
inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional inventional additional inventional inventional inventional inventional inventional inventional additional inventional
William J. Jianping Lingyan Xiaoxiang Guoqing Zhaoning Jared N. Zhong-Yue Andrew Ying Ulrich
Greenlee Pan Wang Liu Li Zhu Cumming Sun Stamford Huang Iserloh